PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results

C. H. Huang; S. K. Williamson; P. J. VanVeldhuizen; C. T. Hsueh; A. Allen; H. Smith; M. Mayo; O. Tawfik; A. M. Uypeckcuat; K. Kelly

doi:10.1200/jco.2008.26.15_suppl.19055

PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results

C. H. Huang, S. K. Williamson, P. J. VanVeldhuizen, C. T. Hsueh, A. Allen, H. Smith, M. Mayo, O. Tawfik, A. M. Uypeckcuat, K. Kelly

Hematology/Oncology Division

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	American English
Pages (from-to)	19055-19055
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	26
Issue number	15_suppl
DOIs	https://doi.org/10.1200/jco.2008.26.15_suppl.19055
State	Published - May 20 2008

Disciplines

Medicine and Health Sciences
Pathology

Access to Document

10.1200/jco.2008.26.15_suppl.19055License: Unspecified

OpenUrl availability

Full text

Cite this

Huang, C. H., Williamson, S. K., VanVeldhuizen, P. J., Hsueh, C. T., Allen, A., Smith, H., Mayo, M., Tawfik, O., Uypeckcuat, A. M., & Kelly, K. (2008). PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results. Journal of Clinical Oncology, 26(15_suppl), 19055-19055. https://doi.org/10.1200/jco.2008.26.15_suppl.19055

PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results. / Huang, C. H.; Williamson, S. K.; VanVeldhuizen, P. J. et al.
In: Journal of Clinical Oncology, Vol. 26, No. 15_suppl, 20.05.2008, p. 19055-19055.

Research output: Contribution to journal › Meeting abstract › peer-review

Huang, CH, Williamson, SK, VanVeldhuizen, PJ, Hsueh, CT, Allen, A, Smith, H, Mayo, M, Tawfik, O, Uypeckcuat, AM & Kelly, K 2008, 'PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results', Journal of Clinical Oncology, vol. 26, no. 15_suppl, pp. 19055-19055. https://doi.org/10.1200/jco.2008.26.15_suppl.19055

Huang CH, Williamson SK, VanVeldhuizen PJ, Hsueh CT, Allen A, Smith H et al. PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results. Journal of Clinical Oncology. 2008 May 20;26(15_suppl):19055-19055. doi: 10.1200/jco.2008.26.15_suppl.19055

@article{c9e7fc5962584979b22fb87bd1d6b492,

title = "PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results",

author = "Huang, {C. H.} and Williamson, {S. K.} and VanVeldhuizen, {P. J.} and Hsueh, {C. T.} and A. Allen and H. Smith and M. Mayo and O. Tawfik and Uypeckcuat, {A. M.} and K. Kelly",

note = "19055 Background: Anti-angiogenesis is the new paradigm in the management of non-small cell lung cancer. Platelet Derived Growth Factor Receptor alpha (PDGFR-alpha) is involved in angiogenesis and its expression has been found in lung cancer. Preclinical models have shown that I inhibit PDGFR and may subsequently inhibit angiogenesis.",

year = "2008",

month = may,

day = "20",

doi = "10.1200/jco.2008.26.15_suppl.19055",

language = "American English",

volume = "26",

pages = "19055--19055",

journal = "Journal of Clinical Oncology",

number = "15_suppl",

}

TY - JOUR

T1 - PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results

AU - Huang, C. H.

AU - Williamson, S. K.

AU - VanVeldhuizen, P. J.

AU - Hsueh, C. T.

AU - Allen, A.

AU - Smith, H.

AU - Mayo, M.

AU - Tawfik, O.

AU - Uypeckcuat, A. M.

AU - Kelly, K.

N1 - 19055 Background: Anti-angiogenesis is the new paradigm in the management of non-small cell lung cancer. Platelet Derived Growth Factor Receptor alpha (PDGFR-alpha) is involved in angiogenesis and its expression has been found in lung cancer. Preclinical models have shown that I inhibit PDGFR and may subsequently inhibit angiogenesis.

PY - 2008/5/20

Y1 - 2008/5/20

UR - https://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.19055

UR - https://www.mendeley.com/catalogue/f19736db-aaa2-35a2-8f34-2f8881972e27/

U2 - 10.1200/jco.2008.26.15_suppl.19055

DO - 10.1200/jco.2008.26.15_suppl.19055

M3 - Meeting abstract

VL - 26

SP - 19055

EP - 19055

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15_suppl

ER -

PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results

Disciplines

Access to Document

OpenUrl availability

Other files and links

Cite this